Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is guselkumab off patent in u s?What are alcohol's effects on ozempic?Motegrity ingredients?What excipients are combined with ruxolitinib in apotex's medication?How does renal function impact tigecycline's liver safety?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin (brand name Zepzelca) gained accelerated FDA approval in June 2020 for adults with metastatic small cell lung cancer (SCLC) that progressed after platinum-based chemotherapy.[1] The pivotal trial was a multicenter, open-label phase 2 basket trial (PM14-504) with 105 patients, primarily those with relapsed SCLC (80%). The primary endpoint was overall response rate (ORR) by independent review, hitting 35% (95% CI: 26-45).[1][2]
In the SCLC cohort: - Sensitive relapse (first-line response ≥90 days): ORR 51% (20/39 patients). - Resistant relapse (<90 days): ORR 22% (13/60 patients).[2] Median duration of response was 5.3 months overall, with 46% of responders maintaining response at 6 months.[1] Median progression-free survival (PFS) was 3.5 months; overall survival (OS) was 9.3 months.[2] Updated analyses from the phase 3 confirmatory trial (ORR 41% with immunotherapy combo) supported full approval in 2024.[3]
Lurbinectedin outperformed topotecan (historical ORR 15-24% in similar SCLC patients) and showed non-inferior OS in head-to-head trials.[2][4] It's not first-line but second-line standard now.
Phase 3 trials like LAGOON (NCT05143218, first-line SCLC with atezolizumab) report interim ORR around 60-70% in combos, but monotherapy data remains from smaller relapsed cohorts.[5] Success varies by prior immunotherapy exposure—lower ORR (25%) post-anti-PD-1.[2] No large-scale data for non-SCLC uses yet. [1]: FDA Approval Summary: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer [2]: Trigo et al., Lancet Oncology (2020): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30268-0/fulltext [3]: ASCO 2024 Abstract: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8503 [4]: Paz-Ares et al., Lancet Oncology (2021): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00065-2/fulltext [5]: ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05143218
Other Questions About Lurbinectedin :